In recent years, there has been a noticeable increase in clinical trials of anticancer drugs in China.
Specifically, imaging endpoints derived from medical imaging assessments as surrogate endpoints are being chosen for more clinical trials.
In January 2021, the Centre for Drug Evaluation of China, the CDE, published guidance for the imaging endpoint process, especially focusing on antitumor clinical trials.
In this video, we compare the content of the China’s CDE guidance with Clinical Trial Imaging Endpoint Process Standards: Guidance for Industry, the U.S. FDA guidance. It will mainly provide an introduction of the similar considerations and differences between the two.
Contacts
Micron, Inc.
E-mail：imagingbiomarker@micron-kobe.com
Category
Please feel free to contact us
We provide comprehensive, end‑to‑end clinical development support, with imaging at its core.
With more than 20 years of experience, our team of imaging specialists in Japan and around the world tackles the complex challenges of imaging evaluation in pharmaceutical and medical device development. We deliver optimal, project‑specific solutions for each client.